邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

《中国老年2型糖尿病防治临床指南（2022年版）》解读

赵维纲

downloadPDF
文章导航 > 协和医学杂志  > 优先出版
赵维纲. 《中国老年2型糖尿病防治临床指南（2022年版）》解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0199
引用本文: 赵维纲. 《中国老年2型糖尿病防治临床指南（2022年版）》解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0199
shu
ZHAO Weigang. Interpretation on clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0199
Citation: ZHAO Weigang. Interpretation on clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0199
shu

《中国老年2型糖尿病防治临床指南（2022年版）》解读

doi: 10.12290/xhyxzz.2022-0199

  • 中国医学科学院北京协和医院内分泌科 国家卫生健康委内分泌重点实验室, 北京 100730

详细信息
    通讯作者:

    赵维纲,E-mail:xiehezhaoweigang@163.com

  • 中图分类号: R587.1

Interpretation on clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China

  • Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences&Peking Union Medical College, Beijing 100730, China

    摘要
  • 摘要: 根据我国第七次人口普查数据，2020年我国老年（≥60岁）人口占全国总人口的18.7%，其中约30%（7813万）的老年人患有糖尿病，且95%以上为2型糖尿病。目前我国老年2型糖尿病的防治现状不佳，且存在弱化和消极趋势，其所带来的并发症成为危害老年人健康的主要原因。《中国老年2型糖尿病防治临床指南（2022年版）》汇总了国内外老年糖尿病相关研究信息，为优化我国老年糖尿病防治理念、促进临床诊疗规范化、提高老年糖尿病总体管理水平提供了循证医学证据。本文对其重要内容进行解读，以期更好地指导临床实践。
    Abstract: According to the data of China's seventh national population census, the elderly population (≥ 60 years old) accounted for 18.7% (260.4 million) of the total population in 2020. About 30%(78.13 million) of them suffer from diabetes mellitus, and more than 95% have type 2 diabetes mellitus. However, the current prevention and treatment of elderly type 2 diabetes mellitus is unsatisfactory, there is a tendency of weakening and negativity. Complications caused by poorly controlled blood glucose are the main risk factors for healthy survival of the elderly. The Clinical guidelines of prevention and treatment of elderly type 2 diabetes mellitus in China (2022 edition), summarizing the domestic and foreign relevant guidelines and research on elderly diabetes mellitus, aims to establish and optimize the concept of prevention and treatment in elderly diabetes mellitus, promote the implementation of standardized prevention and treatment measures, and constantly improve the overall management level of elderly diabetes mellitus. Therefore, it is necessary to interpret its important contents.
    • HTML全文
    • 参考文献(39)
  • [1] 中国老年2型糖尿病防治临床指南编写组.中国老年2型糖尿病防治临床指南(2022年版)[J].中国糖尿病杂志,2022,30:2-51.
    [2] Li Y, Teng D, Shi XG, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:national cross sectional study[J]. BMJ,2020,369:m997.
    [3] Pan XR, Yang WY, Li GW, et al. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group[J]. Diabetes Care, 1997, 20:1664-1669.
    [4] Yang W, Lu J, Weng J, et a1. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010,362:1090-1101.
    [5] Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310:948-959.
    [6] Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabete and Prediabetes in China in 2013[J]. JAMA,2017,317:2515-2523.
    [7] 国家统计局(2021-05-11)第七次全国人口普查公报(第五号)[EB/OL]. (2021-05-11)[2022-04-11].http://www.stats.gov.cn/tjsj/tjgb/rkpcgb/qgrkpcgb/202106/t20210628_1818824.html.
    [8] Yan ST, Li CX, Li CL, et al. Promotive effect of comprehensive management on achieving blood glucose control in senile type 2 diabetics[J]. Genet Mol Res, 2015,14:3062-3070.
    [9] Tinsley LJ, Kupelian V, D'Eon SA, et al. Association of Glycemic Control With Reduced Risk for LargeVessel Disease After More Than 50 Years of Type 1 Diabetes[J]. J Clin Endocrinol Metab, 2017,102:3704-3711.
    [10] Thompson TJ, Engelgau MM, Hegazy M,et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults[J]. Diabet Med,1996,13:337-340.
    [11] Hou JN, Bi YF, Xu M, et al. The change points of HbA(1C) for detection of retinopathy in Chinese type 2 diabetic patients[J]. Diabetes Res Clin Pract,2011,91:401-405.
    [12] Lindström J, Peltonen M, Eriksson JG, et al. Improved lifestyle and decreased diabetes risk over 13 years:long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS)[J]. Diabetologia, 2013,56:284-293.
    [13] Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus:a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance[J]. Lancet, 2009,373:1607-1614.
    [14] Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes[J]. N Engl J Med, 2008,358:580-591.
    [15] Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria:21 years follow-up on the Steno-2 randomised trial[J]. Diabetologia, 2016,59:2298-2307.
    [16] ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2008, 358:2560-2572.
    [17] Gerstein HC, Riddle MC, Kendall DM,et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial[J]. Am J Cardiol, 2007,99:34i-43i.
    [18] van Hateren KJ, Landman GW, Kleefstra N, et al. Glycaemic control and the risk of mortality in elderly type 2 diabetic patients (ZODIAC-20)[J]. Int J Clin Pract, 2011,65:415-419.
    [19] American Diabetes Association. Glycemic Targets:Standards of Medical Care in Diabetesd 2018[J]. Diabetes Care, 2018,41:S55-S64.
    [20] Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by The American Association of Clinical Endocrinologists and American College of Endocrinology on The Comprehensive Type 2 Diabetes Management ALGORITHM-2017 Executive Summary[J].Endocr Pract, 2017,23:207-238.
    [21] Araki E, Haneda M, Kasuga M et al. New glycemic targets for patients with diabetes from the Japan Diabetes Society[J].J Diabetes Investig,2017,8:123-125.
    [22] Lu JY, Ma XJ, Zhou J, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes[J].Diabetes Care,2018,41:2370-2376.
    [23] 戴冬君,陆静毅,张磊,等.应用葡萄糖在目标范围内时间评价2型糖尿病血糖控制情况的适宜切点分析[J].中华医学杂志, 2020,100:2990-2996.
    [24] Lu J, Wang C, Shen Y, et al. Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes:A Prospective Cohort Study[J].Diabetes Care, 2021, 44:549-555.
    [25] Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation:recommendations from the international consensus on time in range[J]. Diabetes Care, 2019, 42:1593-1603.
    [26] 中国老年保健医学研究会老年内分泌与代谢病分会,中国毒理学会临床毒理专业委员会.老年人多重用药安全管理专家共识[J].中国全科医学, 2018,21:3533-3544.
    [27] Norwood P, Liutkus JF, Haber H, et al. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years[J]. Clin Ther, 2012,34:2082-2090.
    [28] Kadowaki T, Nangaku M, Hantel S, et al. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease:Results from the EMPA-REG OUTCOME® trial[J]. J Diabetes Investig,2019,10:760-770.
    [29] Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes:an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol[J]. 2019,7:606-617.
    [30] Gomes MB, Rathmann W, Charbonnel B, et al. Treatment of type 2 diabetes mellitus worldwide:Baseline patient characteristics in the global DISCOVER study. Diabetes Res Clin Pract[J]. 2019,151:20-32.
    [31] Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes:updated systematic review and meta-analysis[J]. Lancet,2016,387:435-443.
    [32] 高尿酸血症相关疾病诊疗多学科共识专家组.中国高尿酸血症相关疾病诊疗多学科专家共识[J].中华内科杂志,2017,56:235-248.
    [33] 中华医学会内分泌学分会.中国高尿酸血症与痛风诊疗指南(2019)[J].中华内分泌代谢杂志, 2020,36:1-13.
    [34] Ferrari SL, Abrahamsen B, Napoli N, et al. Diagnosis and management of bone fragility in diabetes:an emerging challenge[J]. Osteoporos Int,2018,29:2585-2596.
    [35] 吴芸杨,陈晓宏,季晶俊,等.肌肉衰减综合征的诊断和治疗进展[J].医学综述,2020,26:4499-4503.
    [36] Boccardi V, Murasecco I, Mecocci P. Diabetes drugs in the fight against Alzheimer's disease[J]. Ageing Res Rev,2019,54:100936.
    [37] Lee AA, Piette JD, Heisler M, et al. Diabetes self-management and glycemic control:The role of autonomy support from informal health supporters[J]. Health Psychol,2019,38:122-132.
    [38] Lee AA, Heisler M, Trivedi R, et al. Autonomy support from informal health supporters:links with selfcare activities, healthcare engagement, metabolic outcomes, and cardiac risk among Veterans with type 2 diabetes[J]. J Behav Med, 2021,44:241-252.
    [39] Koetsenruijter J, Eikelenboom Nv, Lieshout Jv, et al. Social support and self-management capabilities in diabetes patients:An international observational study[J]. Patient Educ Couns,2016,99:638-643.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  13
  • HTML全文浏览量:  2
  • PDF下载量:  14
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-05-09
  • 网络出版日期:  2022-06-11

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计